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Abstract
Background: Central pain (CP) is a common clinical problem in patients with spinal cord injury (SCI). Recent
studies found the pathogenesis of CP was related to the remodeling of the brain. We investigate the roles of iron
overload and subsequent oxidative stress in the remodeling of the brain after SCI.
Methods: We established a rat model of central pain after SCI. Rats were divided randomly into four groups: SCI, sham
operation, SCI plus deferoxamine (DFX) intervention, and SCI plus nitric oxide synthase (NOS) inhibitor treatment. Pain
behavior was observed and thermal pain threshold was measured regularly, and brain levels of iron, transferrin receptor 1
(TfR1), ferritin (Fn), and lactoferrin (Lf), were detected in the different groups 12 weeks after establishment of the model.
Results: Rats demonstrated self-biting behavior after SCI. Furthermore, the latent period of thermal pain was reduced
and iron levels in the hind limb sensory area, hippocampus, and thalamus increased after SCI. Iron-regulatory protein
(IRP) 1 levels increased in the hind limb sensory area, while Fn levels decreased. TfR1 mRNA levels were also increased
and oxidative stress was activated. Oxidative stress could be inhibited by ferric iron chelators and NOS inhibitors.
Conclusions: SCI may cause intracranial iron overload through the NOS–iron-responsive element/IRP pathway,
resulting in central pain mediated by the oxidative stress response. Iron chelators and oxidative stress inhibitors can
effectively relieve SCI-associated central pain.
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Background
Spinal cord injury (SCI) refers to pathological changes
including motor, sensory, and sphincter dysfunction and
dystonia, as well as pathological reflexes of the corre-
sponding spinal segment following damage by direct or
indirect factors. Previous studies have concentrated on
the recovery of motor and sensory functions and have
tended to ignore SCI-associated complications. However,
central pain is a common complication of SCI, with an
incidence as high as 77–86% [1, 2]. Central pain (CP) is
a neuropathic syndrome associated with hypersensitivity
to pain caused by spinal cord or brain injury. It is often
associated with persistent and intolerable lower limb
pain [3, 4], which can seriously affect sleep, self-care,
rehabilitation, and quality of life. However, the pathogen-
esis of CP is unclear and only empirical therapy can be
applied, leading to pain relief in only 20–30% of patients
[5]. CP after SCI has thus become a major problem in
the field of spinal injury rehabilitation.
The mechanisms of SCI-associated central pain are
currently unclear, and the numerous hypotheses pro-
posed to date have been unable to explain fully the
mechanisms responsible for structural and functional re-
modeling in the brains of patients with CP [6]. However,
increasing evidence suggests that structural and func-
tional remodeling of the brain is a key causative factor in
SCI-associated CP [7, 8].
Previous studies have shown that intracranial iron
overload plays an important role in the development
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and progression of some central nervous system dis-
eases, such as Alzheimer’s disease, Parkinson’s disease,
and cerebral hemorrhage [9–11]. It has also been sug-
gested that oxidative stress injury of neurons is related
to iron toxicity via the Fenton reaction; peroxidation
may affect neuronal ATPase activity, inhibit calcium
influx, mediate inflammation [12, 13], and ultimately
lead to neuronal injury or loss [14, 15].
In this study, we investigated the occurrence and
mechanisms of intracranial iron overload after SCI and
determined if iron overload could further induce oxida-
tive stress injury in a rat model of CP. We also examined
the effects of iron chelators and oxidative stress inhibi-
tors, to clarify the effects of iron-induced oxidative stress
on neurons and the role of iron overload in oxidative
stress injury and central pain after SCI.
Methods
Experimental design
Sixty female Sprague–Dawley rats (228.0 ± 16.0 g) were
divided randomly into four groups: sham operation
group (laminectomy without SCI or other interventions),
control group (spinal injury without other interventions),
L-arginine group (spinal injury plus intraperitoneal injec-
tion of 1.5 mg/kg L-arginine on the first day after the op-
eration, followed by once a week to the end of the
experiment), and deferoxamine (DFO) group (spinal in-
jury plus intraperitoneal injection of 100 mg/kg DFO on
the first day after the operation, followed by once a week
to the end of the experiment).
Establishment of rat model of SCI
Rats were anesthetized with 10% chloral hydrate (3 ml/kg),
and the T9–T11 spinous processes and lamina were
exposed under aseptic conditions. T10 laminectomy was
performed and the impact area (2–3 mm long) was ex-
posed. The Allen impact method was used to establish the
SCI model. Rats in the sham operation group underwent
the same laminectomy procedure, but without impact. Rats
were fed individually after the operation, and 0.6 g linco-
mycin was injected intramuscularly within 3 days. Bladder
squeezing was conducted to help urination until the rats
could urinate independently. In the case of death during
feeding, new animals were supplemented.
Assessment of pain behavior
Spontaneous pain reactions were observed after the
operation, including grooming the hind limbs and tail,
scratching, licking, and spontaneous screaming.
Measurement of paw-withdrawal latency (PWL)
PWL was measured at 2, 4, 8, 12, 16, and 24 h after the
operation, and an intelligent hot plate was used to
measure PWL every day thereafter. The rats’ paws were
pressed onto a hot plate at 55 °C, and the withdrawal re-
action time was recorded. The procedure was performed
three times within a 3-min interval and the final result
was the average value.
Determination of iron levels in the brain cortex
Iron levels in the whole brain and in various brain areas
were measured by atomic absorption spectrophotometry.
Whole brains or the hind limb sensory areas, thalamus,
and hippocampus were collected and weighed, immersed
in 20 mmol/1 HEPES buffer (1:20, w/v), and homogenized.
A 30-μl volume of homogenate was mixed with an equal
volume of ultrapure nitric acid and digested in a 50 °C
water bath for 48 h, then diluted with 3.12 mmol/l nitrate
at a 1:10 ratio. A standard curve was prepared using iron
solution (50 mg/l) diluted with 5% nitric acid. The blank
and sample tubes were measured three times and the ab-
sorbance values at 248.3 nm were recorded for analysis.
Detection of transferrin receptor 1 (TfR1) messenger RNA
(mRNA) levels by reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from the hind limb sensory cor-
tex, hippocampal, and thalamus tissues of three rats in each
group using a TRIzol reagent (Invitrogen, Carlsbad, CA,
USA), and 20 μg of RNA was treated with 10 U DNaseI
(Takara Bio, Otsu, Japan) for 30 min at 37 °C. cDNA was
synthesized using oligo dT primer, and 1 μl was added to
the reaction containing 27.5 μl Real-Time PCR Master
Mix(TOYOBO), 15 pmol of primers, and 7.5 pmol TaqMan
probe, for a total volume of 30 μl. Primers and probes for
TfR1 and ferritin (Fn) were designed with Primer Premier
5.0 software and synthesized by Shenggong Biotechnology
(Shanghai, China). The sequences were as follows: Tfrc-F,
CGT GGA GAC TAC TTC CGT GC and Tfrc-R, GCC
AGA GCC CCA GAA GAT GTG; GAPDH-F, GCAA
GTTCAACGGCACAG, and GAPDH-R, CCATGGTG
GTGAAGACGCCA.
Measurement of TfR1 and Fn levels in the primary
sensory cortex, thalamus, and hippocampus by
enzyme-linked immunosorbent assay (ELISA)
Hind limb sensory cortex, hippocampus, and thalamus
tissues were collected from five rats in each group and
homogenized in radioimmunoprecipitation assay buffer
containing protease and phosphatase inhibitors and phe-
nylmethylsulfonyl fluoride at 4 °C. The homogenate was
centrifuged at 10,000 rpm for 30 min, and the super-
natant was collected and stored at −70 °C. The protein
content of each sample was determined with the
bicinchoninic acid assay. TfR1 and Fn levels were deter-
mined by ELISA (abcam). Each sample was prepared in
triplicate, and optical density values were calculated as
mean ± standard deviation.
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Detection of protein expression levels of iron-regulatory
protein 1 (IRP1), Fn, and lactoferrin (Lf) in the hind limb
sensory cortex by Western blot
IRP1, Fn, Lf, and NF-κB protein levels in the hind limb
sensory cortex of rats in each group were determined by
western blotting. Briefly, 50 μg protein from brain tissue
lysates were resolved by 10% non-denaturing sodium do-
decyl sulfate-polyacrylamide gel electrophoresis and trans-
ferred to a nitrocellulose membrane, which was confirmed
by Ponceau S staining. The membrane was blocked with
skim milk powder at room temperature for 2 h, followed
by overnight incubation at 4 °C with rat anti-human IRP1
(Santa Cruz Biotechnology, USA) (1:100), rabbit anti-
human Fn (1:100, PLLABS), rabbit anti-rat NF-κB (1:400,
abcam), rabbit anti-rat LF (Santa Cruz Biotechnology,
USA) (1:200), and anti-β-actin (1:100) antibodies. After
three washes with Tris-buffered saline containing 0.05%
Tween 20, the membrane was incubated with horseradish
peroxidase-conjugated secondary antibody (1:500) at
room temperature. The enhanced chemiluminescence de-
tection kit (Pierce, Rockford, IL, USA) was used to detect
protein bands, which were analyzed using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
Measurement of superoxide dismutase (SOD) and
malondialdehyde (MDA) in rat brain tissues
Hind limb sensory cortex, hippocampus, and thalamus
tissues were collected from five rats in each group,
weighed, and put into a −20 °C glass homogenizer, with
the addition of 9× pre-cooled normal saline to prepare
the tissue homogenate. Samples were centrifuged for
15 min at 3500 r/min at 4 °C, and the supernatants were
collected. SOD was detected at 550 nm and MDA at
532 nm, according to the manufacturer’s instructions.
SOD and MDA levels were calculated as follows: SOD
content (U/mg prot) = (CA −TA)/CA ÷ 50% × total volume
of reaction solution/sample volume ÷ TP (mg prot/ml),
and MDA (U/mg prot) = (OD value of target tube −OD
value of standard blank tube)/(OD value of standard
tube −OD value of the standard blank tube) × concentration
(10 nmol/ml) of standard ÷ TP (mg prot/mL).
Statistical analysis
Statistical analysis was performed using SPSS 17.0.
Results were presented as mean ± standard deviation
(SD). Intergroup comparisons were analyzed by ANOVA.
P < 0.05 was defined as statistically significant.
Results
Self-biting
Behaviors including scratching, biting, and excessive
grooming below the injured segment (hind paws and
tail) were observed in rats with SCI, but not in rats in
the sham operation group. Within 1 month after oper-
ation, the number of rats with skin breakage below the
level of injury in different groups is as follows: 8/15 in
SCI group, 9/15 in L-arginine group, 6/15 in DFO group,
and 0/15 in sham operation group. All damaged skin
were sterilized and sutured after found.
Determination of PWL
Mean PWLs were 1.55 ± 0.14 s (SCI group), 2.19 ± 0.09 s
(sham operation group), 1.9 ± 0.11 s (L-arginine group),
and 1.89 ± 0.10s (DFO group) (Fig. 1a). The thermal pain
threshold in the sham operation group was significantly
higher than in the other groups (P < 0.05), and the
threshold in the SCI group was significantly lower than
in the other groups (P < 0.05). PWLs were higher in the
sham operation group at all time points compared with




The mean whole-brain iron levels were 11.5 ± 2.1 μg/g
in the SCI group, 12.3 ± 2.6 μg/g in the sham operation
Fig. 1 Paw-withdrawal latency (PWL) in different groups. a Rat PWL. *P < 0.05 compared with control group; △P < 0.05 compared with sham
operation group. b Rat PWLs in different groups
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group, 11.4 ± 1.8 μg/g in the arginine group, and 11.8 ±
3.1 μg/g in the DFO group (Fig. 2a). There were no
significant differences in whole-brain iron levels among
the groups.
Iron levels in functional brain areas
Iron levels in the hind limb sensory area, hippocampus,
and thalamus were significantly lower in the sham oper-
ation group compared with the other groups (P < 0.05)
and were significantly higher in the SCI group relative to
the other groups (P < 0.05) (Fig. 2b; Table 1).
Detection of IRPs in the brain by Western blot
Expression levels of IRP1, Fn, and Lf proteins in the hind
limb sensory area in rats in each groups are shown in
Fig. 3 and Table 2. IRP1 expression was significantly
lower in the sham operation group compared with the
other groups (P < 0.05), while Fn expression was signifi-
cantly higher (P < 0.05). In contrast, IRP1 expression
levels were significantly higher in the SCI and DFO
groups compared with the sham operation and arginine
groups (P < 0.05), and Fn levels were significantly lower in
the SCI group than in the other three groups (P < 0.05).
Treatment with arginine thus reduced IRP expression and
increased Fn expression in the SCI group, while DFO in-
creased Fn expression in the SCI group but had no effect
on IRP1. There were no significant differences in Lf levels
among the groups.
TfR1 and Fn levels in the hind limb sensory area,
thalamus, and hippocampus of rats by ELISA
TfR1 levels were significantly lower in the sham operation
group compared with the other groups (P < 0.05), while
Fn levels were significantly higher (P < 0.05) (Fig. 4;
Tables 3 and 4). In contrast, TfR1 levels were significantly
higher in the SCI group compared with the other groups
(P < 0.05), while Fn levels were significantly lower.
Arginine decreased TfR1 levels after SCI (P < 0.05) and in-
creased Fn levels (P < 0.05), while DFO increased Fn levels
(P < 0.05) but had no effect on TfR1 levels.
TfR1 mRNA expression in the hind limb sensory area,
thalamus, and hippocampus in rats by RT-PCR
TfR1 levels in the hind limb sensory area, thalamus, and
hippocampus in the sham operation group were signifi-
cantly lower than in the other groups (P < 0.05), while
TfR1 levels in these areas were significantly higher in the
SCI group than in the sham operation and arginine
groups (P < 0.05) (Fig. 5; Tables 3 and 4). Arginine and
DFO treatment thus reduced TfR1 mRNA levels after
SCI (P < 0.05), with arginine having a greater effect than
DFO.
SOD and MDA levels in rat brain
MDA levels were significantly lower in the sham oper-
ation group than in the other groups (P < 0.05), while
SOD levels were significantly higher (P < 0.05) (Fig. 6;
Table 5). In contrast, SOD levels were lowest and MDA
levels highest in the SCI group. Arginine and DFO sig-
nificantly reduced MDA and increased SOD levels (P
< 0.05 for both).
Discussion
Central pain
CP, also referred to as dysesthetic pain syndrome or cen-
tral dysesthesia syndrome, is a stubborn and common
complication of SCI, which may develop spontaneously
Fig. 2 Iron levels in whole-brain and functional brain areas. a Whole-brain iron levels and b iron levels in the hind limb sensory cortex, thalamus,
and hippocampus. *Compared with control group, P < 0.05;△compared with sham operation group, P < 0.05
Table 1 Iron levels (μg/g) in the hind limb sensory cortex,
thalamus, and hippocampus in different rat groups (x  s.)
Group SCI Sham Arginine DFO
Hind limb cortex 8.6 ± 1.7 13.2 ± 2.2 10.9 ± 1.9 10.7 ± 1.8
Thalamus 10.3 ± 1.9 21.2 ± 3.1 16.5 ± 2.4 15.9 ± 2.6
Hippocampus 9.8 ± 2.1 18.6 ± 2.6 14.7 ± 1.7 15.1 ± 3.1
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or may be induced by skin irritation [16, 17]. The inci-
dence of CP was reported to be 11–94% in 2 million
patients with SCI, and about one third have severe CP.
Patients may experience a variety of symptoms, includ-
ing knife-like pain, burning pain, tingling, radiating pain,
tight pain, and cold feeling, which may seriously affect
their quality of life [18]. Common treatments for CP
after SCI currently include physical therapy, drugs, and
surgery. However, the efficacies of these treatments are
unsatisfactory, and drug treatment can lead to depres-
sion, drug addiction, and other complications [19]. It is
therefore essential to develop a better understanding of
the pathogenesis of the disease in order to improve its
treatment.
There are several hypotheses regarding the mecha-
nisms of SCI-associated CP, including imbalance of
sensory pathways [20], imbalance of inhibitory and
excitatory receptors [21, 22], problems with pattern-
generating mechanisms [23], and neuroimmunological
mechanisms [24]; however, these hypotheses cannot fully
explain the pathogenesis of CP. Recent studies have
indicated that certain brain regions, such as the somato-
sensory center, thalamus, and limbic system, undergo
remodeling after SCI to compensate for the loss of
sensory function below the injured segment, and many
researchers believe that this remodeling may be a key
factor in SCI-associated CP [25, 26].
Patients with spinal cord transection injuries were
shown to experience pain in the region distal to the
injured segment, while the severity of pain was not
determined by the extent of the injury [27, 28]. We
therefore aimed to seek the source of pain proximal to
the injured segment.
CP includes spontaneous pain caused by injury itself,
with no external stimulus, as well as pain induced by
external stimuli. In this study, we established a rat SCI
model using the Allen impact method [29] and found
that all rats, except those in the sham operation group,
demonstrated excessive grooming behaviors, such as
self-biting and scratching the hind limbs, which may
have been caused by spontaneous pain in the hind limbs.
We also showed that the thermal pain threshold in the
lower extremities was significantly decreased in the SCI/CP
groups, thus triggering hyperalgesia. These results
indicated that both spontaneous and induced pain were
Fig. 3 IRP1, Fn, and LF protein expression in the functional brain areas by Western blot. a Western blot of IRP1, Fn, and LF proteins in the hind
limb sensory area of rats. b The gray ratio of IRP1 and the loading control β-actin were plotted. Data represent the average of three experiments.
c Fn. d Lf. *Compared with SCI group, P < 0.05;△compared with sham operation group, P < 0.05
Table 2 IRP1, Fn, and Lf levels in different rat groups
Group SCI Sham Arginine DFO
IRP1 0.976 ± 0.08 0.589 ± 0.08 0.723 ± 0.11 0.959 ± 0.120
Fn 0.521 ± 0.12 0.832 ± 0.13 0.715 ± 0.07 0.676 ± 0.11
LF 0.931 ± 0.11 0.828 ± 0.04 0.804 ± 0.15 0.749 ± 0.09
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induced in this rat model, in line with previous studies
[30–32]. Treatment with DFO or arginine significantly in-
creased the thermal pain threshold and reduced excessive
grooming behavior, suggesting that these drugs relieved
the induced and spontaneous SCI-associated CP.
Iron overload in the brain
Iron is an important trace element in the human body
and is widely distributed in the brain, where it partici-
pates in many important physiological and biochemical
processes, including DNA, RNA, and protein synthesis,
myelin synthesis, myelinogenesis, and development, as
well as the synthesis of some neurotransmitters such as
dopamine. However, excess iron is toxic to the human
body, and abnormal accumulation of iron in various
brain areas has been found in many neurodegenerative
disorders [33, 34]. Iron is known to induce the produc-
tion of hydroxyl radicals through the Fenton reaction
[35] (Fe2++ H2O2→ Fe3 + ·OH +OH), thus exacer-
bating oxidative stress and leading to tissue and cell
damage.
Iron is redistributed and deposited in certain brain
areas in some neurodegenerative diseases, such as
Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, and Hallervorde–Spatz syndrome [36–38], and
iron levels have also been shown to be increased in brain
areas in animals under stress conditions, such as heat
stress, exercise stress, and seasickness [39, 40]. Although
increased iron levels have not been conclusively identi-
fied as either the cause or consequence of these diseases,
recent studies of genes associated with iron metabolism
in the brain suggest that increased iron is an initiating
factor of neuronal death in some neurodegenerative
diseases [41].
In the present study, we measured iron levels in whole
brain and specific brain areas of rats by atomic ab-
sorption spectrophotometry and found no significant
differences in whole-brain iron levels among the control,
SCI, and SCI + L-arginine- or SCI + DFO-treated rats.
However, iron levels in the thalamus, hippocampus, and
hind limb sensory area were significantly increased in all
SCI/CP groups, with an iron-deposition distribution
similar to that in some neurodegenerative diseases. The
hind limb sensory area is the projection area of the hind
limb in the cortex, while the thalamus and hippocampus
are transit areas of sensory transduction. Lesions in
these areas can cause CP [42, 43]. In the current study,
iron levels in certain brain areas remained elevated
12 weeks after surgery to induce SCI, supporting long-
term deposition of iron in the brain consistent with the
long duration of CP.
The fact that iron levels increased in certain brain areas
but not in the brain as a whole may be attributable to the
function of the blood–brain barrier, which isolates the
brain from the external environment. Although iron levels
increased in some areas, they remained stable overall, con-
sistent with the results of previous studies [44].
Mechanisms of iron overload in the brain
Maintenance of iron homeostasis in the brain depends
on the normal expression and coordination of a variety
of brain iron-metabolism proteins. Penetration of iron
through the blood–brain barrier and the uptake of iron
by neurons are mainly mediated by the classic Tf/TfR
Fig. 4 TfR1 and Fn mRNA expression in the functional brain areas by ELISA. TfR1 and Fn levels in the hind limb sensory area, thalamus, and
hippocampus of rats. a TfR1. b Fn. *Compared with SCI group, P < 0.05;△compared with sham operation group, P < 0.05
Table 3 TfR1 levels in different brain areas measured by ELISA
Group SCI Sham Arginine DFO
Hind limb cortex 9.9 ± 2.4 5.5 ± 1.2 7.3 ± 1.1 9.7 ± 2.4
Thalamus 8.9 ± 2.7 4.1 ± 1.1 6.9 ± 2.3 8.2 ± 2.6
Hippocampus 9.9 ± 1.9 4.9 ± 1.3 7.5 ± 1.8 9.3 ± 3.1
Table 4 Fn levels in different brain areas measured by ELISA
Group SCI Sham Arginine DFO
Hind limb cortex 268.2 ± 43.7 176.2 ± 27.3 204.2 ± 30.9 212.4 ± 22.7
Thalamus 358.2 ± 55.6 258.2 ± 33.0 304.2 ± 41.8 312.0 ± 51.3
Hippocampus 177.4 ± 32.3 288.6 ± 43.1 224.6 ± 24.4 218.6 ± 32.0
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pathway [45–48].We found that TfR1 mRNA and
protein levels were increased in the thalamus, hippo-
campus, and hind limb sensory areas of SCI/CP rats
compared with the sham operation group, suggesting
that iron overload in these brain areas may be caused
by increased iron levels mediated by the Tf/TfR
pathway.
Fn is a natural iron chelator that is widely expressed in
neurons and glial cells in human and rodent animal
brains. Iron stored by Fn accounts for 75% of total brain
iron [49]. The structure of Fn includes H and L
subunits, of which the L subunit is associated with long-
term iron storage [50, 51]. Ferrous iron taken up by
tissue cells is oxidized to ferric iron and sequestered by
Fn and stored in a non-toxic form. [52] Previous studies
have shown that upregulation of Fn may limit iron-
induced brain injury [53]. Furthermore, Fn was found
not to increase in line with increasing iron levels in
Parkinson’s disease and Alzheimer’s disease [54], sug-
gesting that free iron may not be captured and stored by
Fn, and peroxidation caused by free-iron toxicity may
not be prevented.
In this study, levels of the Fn in the thalamus, hippo-
campus, and hind limb sensory area were significantly
decreased in SCI/CP rats compared with the sham oper-
ation group, suggesting that the iron-storage capacity
Fig. 5 TfR1 and Fn mRNA expression in the functional brain areas by RT-PCR. a Melting curve of TfR1. b Hind limb sensory area. c Hippocampus.
d Thalamus. *Compared with SCI group, P < 0.05;△compared with sham operation group, P < 0.05
Fig. 6 SOD and MDA levels in the functional brain areas. a SOD levels in rat brain. b MDA levels in rat brain. *Compared with SCI group, P < 0.05;
△compared with sham operation group, P < 0.05
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was reduced in these areas, potentially leading to in-
creased free iron.
Tfr and Fn play a crucial role in maintaining iron
homeostasis in the brain. Expression levels of these two
proteins are mainly regulated by the iron-responsive
element (IRE)/IRPs. In the absence of iron, IRPs bind to
IREs, which upregulate TfR1 synthesis and downregulate
Fn synthesis. Iron deficiency thus leads to increased iron
uptake and reduced iron storage. In contrast, when iron
is in excess, IRPs do not bind to IREs, TfR1 synthesis is
downregulated, and Fn synthesis is upregulated, leading
to decreased iron intake and increased iron storage.
However, IRP activity is not only regulated by intracellu-
lar iron content. Previous studies found that the IRE/IRP
complex was more stable in the brain of patients with
Alzheimer’s disease. Increased stability of this complex
can stabilize Tfr mRNA levels and decrease Fn synthesis,
thereby increasing iron uptake and decreasing iron stor-
age in the brain in these patients, resulting in brain iron
overload and the induction of oxidative stress and neur-
onal apoptosis.
The results of the current study showed that IRP1 pro-
tein levels were significantly upregulated in the hind
limb sensory area, thalamus, and hippocampus of SCI/
CP rats, compared with the sham operation group, while
TfR was increased and Fn was decreased in these areas.
This suggests that iron regulation was disrupted in these
areas after SCI, and that IRP1 may be the initiating fac-
tor for this process. In addition to the Tf/TfR pathway,
human Lf/Lf receptor may also play a role in iron trans-
port through the blood–brain barrier. However, we
found no differences in Lf expression in the thalamus,
hippocampus, and hind limb sensory area among the
different rat groups, suggesting that Lf-mediated iron
uptake may not be involved in iron overload after SCI.
DFO is a potent iron ion chelating agent, which has
been shown to penetrate the blood–brain barrier rapidly
and accumulate in the brain parenchyma. It can chelate
free iron ions to form a relatively stable compound and
effectively prevent the release of iron ions from Fn, thus
significantly reducing peroxidation damage caused by
iron overload [23]. In our study, DFO significantly re-
duced iron levels in the hippocampus, hind limb sensory
cortex, and thalamus, and increased Fn levels in these
areas, suggesting that DFO may chelate the iron in these
areas and inhibit the degradation of Fn. However, whole-
brain iron levels were not reduced, suggesting that DFO
decreased iron levels by binding iron ions and inhibiting
the formation of free iron, rather than by promoting the
excretion of iron outside the brain.
Iron overload and oxidative stress
There are two types of free radical scavengers in the hu-
man body, antioxidases and antioxidants, which provide
electrons to reduce and block the formation of oxygen
free radicals and thus prevent cell damage. Free radicals
can induce scavenger enzymes to maintain a dynamic
balance [55]. The central nervous system is rich in lipids,
and free radicals can cause lipid peroxidation and induce
pathological changes in cell morphology and function.
Arachidonic acid substances generated by lipid peroxida-
tion, including prostaglandins D2, E2, and I2 and leuko-
trienes, can act on the nerve and glial cells to injure cell
membranes and cause cell dysfunction [56].
SOD and MDA reflect the degree of lipid peroxidation.
MDA is a metabolite of the peroxidation reaction of
membrane unsaturated fatty acids induced by oxygen
free radicals, and an indicator of the degree of cell dam-
age [57]. SOD is a natural antioxidase capable of cleaning
oxygen radicals, thereby blocking the lipid peroxidation
chain reaction, and providing an indicator of the body’s
ability to scavenge oxygen free radicals. Previous studies
found that iron overload increased serum and organ levels
of MDA and reduced SOD [58, 59]. Given that increased
brain iron levels and accompanying oxidative stress have
been identified in many neurodegenerative diseases, some
researchers have suggested that abnormal increases in
brain iron may lead to the generation of large numbers of
free radicals and further induce cell death, which may be
one reason for the observed neuronal death in neurode-
generative diseases. The addition of ferrous sulfate in the
diet has been shown to increase iron ion levels and oxygen
free radicals in rat brains, and to cause neuronal injury,
and even death [12]. Following cerebral hemorrhage and
cerebral ischemia reperfusion, excessive iron ions can
catalyze lipid peroxidation to produce oxygen free
radicals, which attack cell proteins and nucleic acids
leading to peroxidation injury, which represents an im-
portant mechanism of brain injury secondary to cerebral
hemorrhage [60–64]. The potential causative role of
oxidative stress caused by iron overload in the brain in
neurodegenerative diseases is supported by the abnormal
accumulation of iron in certain brain areas in patients
with Parkinson’s disease and Alzheimer’s disease [65].
In the present study, SOD activity was significantly de-
creased and MDA content was significantly increased in
brain tissues of rats with CP. This suggests that large
numbers of oxygen free radicals were produced in the
brain, and that decreased SOD activity caused lipid per-
oxidation injury of biomembranes, which increased the
content of MDA. Intervention with DFO decreased iron
Table 5 SOD and MDA levels in the hind limb sensory area in
different rat groups
Group SCI Sham Arginine DFO
SOD (U/mg) 92.4 ± 20.3 327.4 ± 24.3 204.6 ± 19.8 190.3 ± 17.6
MDA (nmol/mg) 16.57 ± 1.26 3.97 ± 0.67 8.73 ± 0.94 7.88 ± 1.05
Meng et al. Journal of Orthopaedic Surgery and Research  (2017) 12:24 Page 8 of 10
levels and restored SOD activity, associated with de-
creased MDA content.
Conclusions
The results of this study suggest that SCI may trigger
glucocorticoids to activate nitric oxide synthase and fur-
ther activate IRP/IRE, leading to intracranial iron over-
load. Iron overload may in turn cause neuronal injury
via the oxidative stress signaling pathway, resulting in
neuronal damage or loss, and eventually leading to cen-
tral pain. Treatment with iron chelators or nitric oxide
synthase inhibitors may effectively alleviate central pain
after SCI.
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